Atypical bartonellosis in children: What do we know?

被引:14
|
作者
Lemos, Ana P. [1 ]
Domingues, Rui [1 ]
Gouveia, Catarina [1 ]
de Sousa, Rita [2 ]
Brito, Maria J. [1 ]
机构
[1] Hosp Dona Estefania, Dept Infect Dis, Rua Jacinta Marto, P-1169045 Lisbon, Portugal
[2] Natl Inst Hlth Dr Ricardo Jorge, Ctr Study Vectors & Infect Dis, Lisbon, Portugal
基金
美国国家卫生研究院;
关键词
Bartonella infection; encephalitis; fever of unknown origin; lymphadenitis; osteomyelitis; retinitis; CAT-SCRATCH DISEASE; HENSELAE;
D O I
10.1111/jpc.15304
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aim To characterise Bartonella infections in a paediatric population requiring hospital admission and review its treatment. Methods Longitudinal observational retrospective data analysis of children and adolescents admitted with Bartonella infection at a paediatric tertiary hospital from 2010 to 2019. Results We identified 16 cases of bartonellosis, with a mean age of 8.0 +/- 4.5 years old, no sex predominance and 14 had contact with cats. Most of the cases occurred in fall and winter. Clinical presentations included osteomyelitis/arthritis (n = 9), hepatosplenic disease (n = 2), lymphadenitis (n = 2), neuroretinitis (n = 2) and encephalitis (n = 1). Clinical diagnosis was confirmed by serology (n = 16) and Bartonella DNA detection in patient's lymph nodes/hepatic lesion (n = 3). Therapeutic approach varied according to the clinical presentation: azithromycin in lymphadenitis, rifampicin plus ciprofloxacin in hepatosplenic disease, rifampicin and doxycycline in neuroretinitis, ceftriaxone in encephalitis and azithromycin, cotrimoxazole or rifampicin plus azithromycin, cefuroxime, ciprofloxacin or doxycycline in osteomyelitis/arthritis. Immunodeficiency was excluded in seven patients. Seven patients' cats were screened by veterinarians and treated when infected (n = 5). Conclusions In these clinical presentations, where other infections may be involved, a high index of suspicion is necessary, with emphasis on the epidemiological context. The association of systemic forms with immunodeficiency did not occur in our study. The lack of recommendations for treatment of atypical infection makes the approach of these cases a challenge. Randomised control studies are essential to define the best approach in each case.
引用
收藏
页码:653 / 658
页数:6
相关论文
共 50 条
  • [1] Propofol and children - what we know and what we do not know
    Rigby-Jones, Ann E.
    Sneyd, J. Robert
    PEDIATRIC ANESTHESIA, 2011, 21 (03) : 247 - 254
  • [2] Statins in children: what do we know and what do we need to do?
    Black D.M.
    Current Atherosclerosis Reports, 2001, 3 (1) : 29 - 34
  • [3] Atypical fractures and molecular environment: What do we know?
    Elniel, Abdel R.
    Giannoudis, Peter V.
    INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED, 2018, 49 (11): : 1953 - 1958
  • [4] What we know and what we do not know
    McDonald, JC
    RADIATION PROTECTION DOSIMETRY, 2005, 113 (02) : 127 - 128
  • [5] We do not know what we do not know
    Spaeth, GL
    OPHTHALMIC SURGERY AND LASERS, 1999, 30 (05): : 337 - 340
  • [6] We know what they think, but do we know what they do?
    Callingham, M
    Baker, T
    INTERNATIONAL JOURNAL OF MARKET RESEARCH, 2002, 44 (03) : 299 - 335
  • [7] What do we know? What do we need to know?
    Milena J. Henzlova
    W. Lane Duvall
    Journal of Nuclear Cardiology, 2017, 24 : 252 - 254
  • [8] What do we know? What do we need to know?
    Henzlova, Milena J.
    Duvall, W. Lane
    JOURNAL OF NUCLEAR CARDIOLOGY, 2017, 24 (01) : 252 - 254
  • [9] Genetic platforms: Do we do what we know? or do we know what we do?
    Bernet, Laia
    Pla, Maria Jesus
    Janez, Noelia Martinez
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2021, 34 (02): : 100 - 110
  • [10] Quasicrystals: What do we know? What do we want to know? What can we know?
    Steurer, Walter
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2018, 74 : 1 - 11